Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Aquarius Biotechnologies, Inc. (Details 1)

v2.4.1.9
Acquisition of Aquarius Biotechnologies, Inc. (Details 1) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Jan. 29, 2015
Business Acquisition [Line Items]      
Goodwill $ 1,384,674us-gaap_Goodwill $ 0us-gaap_Goodwill  
Aquarius Biotechnologies, Inc. [Member]      
Business Acquisition [Line Items]      
Cash     70,754us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Contract/ Account receivable     45,644us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Prepaid expenses and other current assets     5,084us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Property and equipment, net     5,051us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Other assets     700us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
In-process research and development     3,017,377us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember 		[1]
Total identifiable assets     3,144,610us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Accounts payable     300,413us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Notes payable     10,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember 		[2]
Accrued expenses     92,509us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Total liabilities assumed     402,922us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Net identifiable assets acquired     2,741,688us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Goodwill     1,384,674us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember 		[3]
Deferred income taxes arising from basis differences of tax aspects of in-process research and development     (1,253,327)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Net assets acquired     $ 2,873,035us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
[1] The fair value of the in-process research and development asset was estimated on the basis of its replacement cost as determined by a buildup of the costs incurred to develop the technology as it existed as of the acquisition date resulting in a fair value of $3,017,377. The fair value of other assets and liabilities approximate their book value.
[2] Aquarius issued a note for a loan that was made to a related party. Interest on note is calculated using the applicable federal rate for midterm loans. Since the note has no specified repayment terms, it is considered a current liability.
[3] The Company allocated the purchase price to the net tangible and intangible assets based upon their estimated fair values at the Merger date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired has been recorded as goodwill including deferred tax liabilities resulting from the tax attributes of the in-process research and development (see Note C 14).